Arboretum Ventures — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
Allay Therapeutics develops localized pain management technology designed to deliver several weeks of post-surgical pain relief.
BiotechHealthtechMedical DevicesSan Jose, US
Adam Gridley(Executive Officer, Director)Kristen Howells(Executive Officer)Josh Makower(Director)Tak Cheung(Director)Karun D. Naga(Executive Officer, Director)
BoardLeighton Read(Director)
Board seatPaul McCreadie· per SEC Form D
Co-investorsLightstone VenturesNew Enterprise Associates (NEA)SGInnovateClavystBio
Reprieve Cardiovascular develops a decongestion management system that uses real-time patient data to guide and personalize diuretic therapy for fluid removal in heart failure patients.
Digital HealthHealthtechMedical DevicesMilford, US
Tony Fields(Executive Officer)Adam Bartnik(Executive Officer)Mark Pacyna(Executive Officer, Director)inJim Dillon(Executive Officer, Director)Hanson S. Gifford III(Director)Gregory W Mann(Executive Officer)
Board seatJan Garfinkle· per SEC Form D
Co-investorsLightstone VenturesRex Health VenturesDeerfield Management CompanyGenesis Venture CapitalSante Ventures
Virtual Incision develops a miniaturized robotic-assisted surgery (miniRAS) system called MIRA, designed to fit within hospitals' existing infrastructure.
BiotechHealthtechMedical DevicesRoboticsLincoln, US
Dmitry Oleynikov(Director)Shane Farritor(Executive Officer, Director)John P. Murphy(Executive Officer, Director)Mukund Srinivasan(Executive Officer)
BoardFred Robertson(Director)
Board seatTom Shehab· per SEC Form D
Co-investorsInvest NebraskaInVivium CapitalBaird CapitalEndeavour VisionPrairieGold Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.